ANGPTL3 and atherosclerosis: Recent studies have provided insight into the metabolic role of circulating ANGPTL3 in preclinical models, wherein the treatment with an anti-sense oligonucleotide targeting Angptl3 mRNA in low-density lipoprotein receptor knockout mice resulted in a dramatic reduction of liver TG content, as well as atherosclerosis progression [110].